Astellas Signs DAX-044 Immuno-Oncology License Deal Worth Up to $1.34 Billion
Astellas Pharma and Audax Biosciences announced an exclusive option and license agreement for Audax’s DAX-044 immuno-oncology candidate, with potential deal value of up to $1.34 billion.
TOKYO (dpa-AFX) - Astellas Pharma Inc. (4503.T), a life science company, and Audax Biosciences Pty Ltd., an Australian biotechnology company, announced an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE candidate, in a deal that could be worth up to $1.34 bi…